Compare RANI & TTEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RANI | TTEC |
|---|---|---|
| Founded | 2012 | 1982 |
| Country | United States | United States |
| Employees | N/A | 69400 |
| Industry | Medicinal Chemicals and Botanical Products | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 109.0M |
| IPO Year | 2021 | 1996 |
| Metric | RANI | TTEC |
|---|---|---|
| Price | $0.83 | $2.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 376.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.14 | 40.80 |
| EPS | ★ N/A | N/A |
| Revenue | $1,633,000.00 | ★ $1,509,171,000.00 |
| Revenue This Year | $274.77 | N/A |
| Revenue Next Year | $79.44 | $0.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 58.85 | 2.15 |
| 52 Week Low | $0.44 | $1.91 |
| 52 Week High | $3.87 | $3.99 |
| Indicator | RANI | TTEC |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 63.35 |
| Support Level | $0.69 | $2.05 |
| Resistance Level | $1.18 | $2.66 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 69.56 | 98.44 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
TTEC Holdings Inc provides customer engagement management tools and services. The company operates through two operating segment, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its revenues are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.